Dominari (NASDAQ:DOMH) Stock Price Up 1.3% – What’s Next?

Dominari Holdings Inc. (NASDAQ:DOMH)’s stock price was up 1.3% during trading on Tuesday . The stock traded as high as $3.07 and last traded at $3.01. Approximately 35,956 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 78,665 shares. The stock had previously closed at $2.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, January 12th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Dominari Trading Up 1.3%

The firm has a 50 day moving average of $3.65 and a 200-day moving average of $4.79. The company has a market cap of $48.82 million, a P/E ratio of 0.54 and a beta of 0.83.

Institutional Trading of Dominari

Institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC bought a new position in shares of Dominari during the 4th quarter valued at about $50,000. PFG Investments LLC bought a new stake in shares of Dominari in the fourth quarter worth about $53,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Dominari in the fourth quarter worth about $96,000. Oxford Asset Management LLP purchased a new stake in shares of Dominari in the fourth quarter worth about $120,000. Finally, Jane Street Group LLC bought a new position in Dominari during the second quarter valued at approximately $158,000. 42.48% of the stock is currently owned by institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.